Key result
The article reviews modern guidelines for the treatment and prevention of atrial fibrillation and flutter, highlighting new antiarrhythmic drugs and the authors' experience with propafenone.
Why the study?
Atrial fibrillation and flutter represent the most frequent form of supraventricular sustained tachyarrhythmia, prompting a review of modern etiology, pathogenesis, clinical guidelines, and antiarrhythmic therapies.
This review highlights modern understanding and recent guidelines for the management of atrial fibrillation and flutter, including the use of propafenone at the prehospital stage.
Answers are grounded in this paper and cite their sources.
Supports prehospital propafenone use in paroxysmal AF; extends Level 1 evidence for guideline integration.
The article highlights the modern understanding of etiology, epidemiology and pathogenesis of atrial fibrillation and flutter and their global burden as the most frequent form of supraventricular sustained tachyarrhythmia. The recent international and Russian national clinical guidelines on the treatment and prevention of atrial fibrillation are briefly discussed. The new antiarrhythmic drugs, presented in recent guidelines are also highlighted. The authors analyze their own experience in the treatment of paroxysmal atrial fibrillation with IC class drugs (propafenone) at the prehospital stage.
No takes yet. Share an insight, caveat, or question.
V. I. Shalnev (2023) conducted a review in Atrial fibrillation and flutter. Propafenone was evaluated. The article reviews modern guidelines for the treatment and prevention of atrial fibrillation and flutter, highlighting new antiarrhythmic drugs and the authors' experience with propafenone.
Synapse has enriched 10 related papers. Consider them for comparative context: